The DOI matches its Crossref record; 185 of the 187 references it cites were found in a registry or an index.
Moving towards personalized treatments of immune-related adverse events
Abstract
The enhancement of immune responses upon treatment with immune checkpoint inhibitors can have the desired outcome of reinvigorating antitumour immune surveillance, but often at the expense of immune-related adverse events (irAEs). This novel disease entity often prompts comparisons with, and extrapolation of treatment approaches from, primary autoimmune disorders. Accordingly, current treatment guidelines for irAEs make generic recommendations adapted from the literature describing primary autoimmune diseases, without taking into consideration the substantial disparity of the immunohistopathological findings within each organ affected by an irAE. The treatment modalities themselves are complex and have many potential drawbacks, such as serious and rarely fatal infections, drug toxicities overlapping with irAEs and the risk of compromising cancer immune surveillance. Herein, we provide an overview of key cellular and soluble immunological factors mediating irAEs and propose a model integrating this knowledge with the immunohistopathological findings of the affected organs for a personalized decision-making process for each patient.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although proving to be clinically effective in enhancing T-cell-mediated antitumor responses”
From Autoimmune Myocarditis, Old Dogs and New Tricks. (2024) · cites this paper as [168]
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Bettelli, E., Carrier, Y., Gao, W., Korn, T., Strom, T. B., Oukka, M., Weiner, H. L., & Kuchroo, V. K. (2006) · Nature · doi:10.1038/nature04753 · Cited by 6,992
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Self-citationRole of the microbiota in immunity and inflammation.
Belkaid, Y., & Hand, T. W. (2014) · Cell · doi:10.1016/j.cell.2014.03.011 · Cited by 5,385
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812
An endotoxin-induced serum factor that causes necrosis of tumors
Carswell, E. A., Old, L. J., Kassel, R. L., Green, S., Fiore, N., & Williamson, B. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.9.3666 · Cited by 4,532
Brahmer, J. R., Lacchetti, C., Schneider, B. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., Ernstoff, M. S., Gardner, J. M., Ginex, P., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6385 · Cited by 3,713
Mechanisms of type-I- and type-II-interferon-mediated signalling
Platanias, L. C. (2005) · Nature reviews. Immunology · doi:10.1038/nri1604 · Cited by 3,631
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Vétizou, M., Pitt, J. M., Daillère, R., Lepage, P., Waldschmitt, N., Flament, C., Rusakiewicz, S., Routy, B., Roberti, M. P., Duong, C. P. M., et al. (2015) · Science · doi:10.1126/science.aad1329 · Cited by 3,488
Self-citationMutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237
Cited by
Sorted by citations
Items 101–200 of 352
Shang, J., Hu, S., & Wang, X. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00481-y · Cited by 29
You, L., Zhou, J., Xin, Z., Hauck, J. S., Na, F., Tang, J., Zhou, X., Lei, Z., & Ying, B. (2022) · Precision Clinical Medicine · doi:10.1093/pcmedi/pbac005 · Cited by 30
Exploring the Mechanisms Underlying the Cardiotoxic Effects of Immune Checkpoint Inhibitor Therapies
Ronen, D., Bsoul, A., Lotem, M., Abedat, S., Yarkoni, M., Amir, O., & Asleh, R. (2022) · Vaccines · doi:10.3390/vaccines10040540 · Cited by 29
Liu, Q., Liu, M., Zou, Z., Lin, J., Zhang, N., Zhao, L., Zhou, J., Zhou, H., Zhou, X., Jiao, X., et al. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05617-6 · Cited by 27
Trends in immunotherapy for oral squamous cell carcinoma
Xue, N., Wang, Y., Wang, Z., Zeng, X., Wang, J., & Zhang, X. (2025) · Cellular Oncology · doi:10.1007/s13402-025-01068-3 · Cited by 27
Berner, F., & Flatz, L. (2023) · Immunological Reviews · doi:10.1111/imr.13258 · Cited by 28
Current Technologies and Future Perspectives in Immunotherapy towards a Clinical Oncology Approach
Adhikary, S., Pathak, S., Palani, V., Acar, A., Banerjee, A., Al-Dewik, N. I. E., Essa, M. M., Mohammed, S. G. A. A., & Qoronfleh, M. W. (2024) · Biomedicines · doi:10.3390/biomedicines12010217 · Cited by 28
Dey, S., Trau, M., & Koo, K. M. (2020) · Nanomaterials · doi:10.3390/nano10061145 · Cited by 26
Bardoscia, L., Pasinetti, N., Triggiani, L., Cozzi, S., & Sardaro, A. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.746853 · Cited by 28
Wang, T., Denman, D., Bacot, S. M., & Feldman, G. M. (2022) · Biomedicines · doi:10.3390/biomedicines10051181 · Cited by 27
Kim, G. D., Shin, S.-I., Sun, P., Lee, J. E., Chung, C., Kang, Y. E., Kang, D. H., & Park, J. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-011636 · Cited by 27
Neutrophil extracellular traps in cancer: From mechanisms to treatments
Wang, Y., Yang, K., Li, J., Wang, C., Li, P., & Du, L. (2025) · Clinical and Translational Medicine · doi:10.1002/ctm2.70368 · Cited by 30
Washino, S., Shirotake, S., Takeshita, H., Inoue, M., Miura, Y., Hyodo, Y., Kagawa, M., Izumi, K., Oyama, M., Kawakami, S., et al. (2023) · International Journal of Clinical Oncology · doi:10.1007/s10147-023-02406-x · Cited by 27
Lu, H., Zhu, P., Deng, Y.-Y., Chen, Z., & Yang, L. (2023) · Clinical & Translational Oncology · doi:10.1007/s12094-023-03313-3 · Cited by 26
Wang, Y., Jiang, C., Zhou, H., & Han, R. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00705-9 · Cited by 25
Siddiqui, B. A., Gheeya, J., Goswamy, R. V., Bathala, T. K., Surasi, D. S., Gao, J., Shah, A. Y., Campbell, M. T., Msaouel, P., Goswami, S., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002850 · Cited by 24
Deharo, F., Carvelli, J., Cautela, J., Garcia, M., Sarles, C., de Paula, A. M., Bourenne, J., Gainnier, M., & Bichon, A. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11195611 · Cited by 27
AND-gated protease-activated nanosensors for programmable detection of anti-tumour immunity
Sivakumar, A., Phuengkham, H., Rajesh, H., Mac, Q. D., Rogers, L. C., Trenkle, A. D. S., Bawage, S. S., Hincapie, R., Li, Z., Vainikos, S., et al. (2025) · Nature Nanotechnology · doi:10.1038/s41565-024-01834-8 · Cited by 25
Chatzidionysiou, K., Liapi, M., Tsakonas, G., Gunnarsson, I., & Catrina, A. (2020) · Clinical Rheumatology · doi:10.1007/s10067-020-05420-w · Cited by 24
Bioengineered immunomodulatory organelle targeted nanozymes for photodynamic immunometabolic therapy
Sunil, V., Teoh, J. H., Mohan, B. C., Mozhi, A., & Wang, C. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.08.025 · Cited by 23
Immunogenetic variations predict immune-related adverse events for PD-1/PD-L1 inhibitors
Xin, Z., You, L., Na, F., Li, J., Chen, M., Song, J., Bai, L., Chen, J., Zhou, J., & Ying, B. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.01.034 · Cited by 23
Immune checkpoint inhibitor-associated myocarditis: a historical and comprehensive review
Jensen, G. L., Wang, X., Kuempel, J., Palaskas, N. L., Chen, Z., Yu, W., Chen, Y., Mohammad, H., Luo, W., & Chang, J. (2025) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00687.2024 · Cited by 24
Ajgal, Z. C., Goulvestre, C., Zaibet, S., Arrondeau, J., Bretagne, M., Peyromaure, M., Batteux, F., Alexandre, J., Goldwasser, F., & Huillard, O. (2022) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2022.04.002 · Cited by 22
Zhang, Z., Xie, T., Qi, C., Zhang, X., Shen, L., & Peng, Z. (2022) · Cancers · doi:10.3390/cancers14153736 · Cited by 25
Chen, P., Zhu, J., Xu, Y., Huang, Q., Su, J., Gao, Z., & Feng, M. (2023) · BMC Nephrology · doi:10.1186/s12882-023-03171-9 · Cited by 23
Kawsar, A., Hussain, K., Muinonen‐Martin, A., & Fearfield, L. A. (2023) · British Journal of Dermatology · doi:10.1093/bjd/ljad257 · Cited by 22
Lin, X., Deng, H., Chen, L., Wu, D., Chen, X., Yang, Y., Chen, T., Xie, X., Xie, Z., Liu, M., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-1258 · Cited by 23
Han, Y., Wang, J., & Xu, B. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103376 · Cited by 22
Dual-locked fluorescent probes for precise diagnosis and targeted treatment of tumors
Gao, T., Xiang, C., Ding, X., & Xie, M. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e38174 · Cited by 22
Connecting the dots: Targeting the microbiome in drug toxicity
Luo, Y., & Zhou, T. (2021) · Medicinal Research Reviews · doi:10.1002/med.21805 · Cited by 20
Current Adenosinergic Therapies: What Do Cancer Cells Stand to Gain and Lose?
Kotulová, J., Hajdúch, M., & Džubák, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212569 · Cited by 21
Yu, Y., Chen, N., Yu, S., Shen, W., Zhai, W., Li, H., & Fan, Y. (2024) · Cancer Research and Treatment · doi:10.4143/crt.2023.1118 · Cited by 21
Wang, W., Wang, Q., Xu, C., Li, Z., Song, Z., Zhang, Y., Cai, X., Zhang, S., Lian, B., Li, W., et al. (2022) · Thoracic Cancer · doi:10.1111/1759-7714.14693 · Cited by 20
Siciliano, M. A., Dastoli, S., D’Apolito, M., Staropoli, N., Tassone, P., Tagliaferri, P., & Barbieri, V. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.579445 · Cited by 20
Natural Language Processing for Radiation Oncology: Personalizing Treatment Pathways
Lin, H., Ni, L., Phuong, C., & Hong, J. C. (2024) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s396971 · Cited by 22
Gill, G. S., Kharb, S., Goyal, G., Das, P., Kurdia, K. C., Dhar, R., & Karmakar, S. (2025) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2025.2504906 · Cited by 19
Case Report: Treatment for steroid-refractory immune-related myocarditis with tofacitinib
Xing, Q., Zhang, Z., Zhu, B., Lin, Q., Shen, L., Li, F., Xia, Z., & Zhao, Z. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.944013 · Cited by 19
Rajendram, P., Torbic, H., Duggal, A., Campbell, J., Hovden, M., Dhawan, V., Pastores, S. M., & Gutiérrez, C. (2021) · Journal of Critical Care · doi:10.1016/j.jcrc.2021.05.020 · Cited by 18
mTOR‐dependent immunometabolism as Achilles' heel of anticancer therapy
Braun, C., & Weichhart, T. (2021) · European Journal of Immunology · doi:10.1002/eji.202149270 · Cited by 18
Guo, M., Fang, W., & Hu, Z. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1429483 · Cited by 17
Chen, Y., Luo, Y., Liu, Y., Luo, D., & Liu, A. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03899-9 · Cited by 18
Acute kidney injury associated with immune checkpoint inhibitors: A pharmacovigilance study
Zhu, J., Wu, J., Chen, P., You, K., Su, J., Gao, Z., Bi, Z., & Feng, M. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109350 · Cited by 18
Jacoberger-Foissac, C., Blake, S. J., Liu, J., McDonald, E., Triscott, H., Nakamura, K., Smyth, M. J., & Teng, M. W. L. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001687 · Cited by 17
Dowling, J. P., Nikitin, P. A., Shen, F., Shukla, H., Finn, J. P., Patel, N. B., Swider, C. R., Bingaman, J. L., Nicolescu, C., Sikorski, E. L., et al. (2023) · mAbs · doi:10.1080/19420862.2023.2212673 · Cited by 16
Zhou, C., Yang, Y., Lin, X., Fang, N., Chen, L., Jiang, J., Deng, H., Deng, Y., Wan, M., Qiu, G., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.935779 · Cited by 16
Yin, Y., Chen, Z., Yang, C., Du, H., Jiang, G., Ji, D., & Dai, J. (2025) · ACS Nano · doi:10.1021/acsnano.5c01888 · Cited by 15
Kunimasa, K., Inoue, T., Matsueda, K., Kawamura, T., Tamiya, M., Nishino, K., & Kumagai, T. (2021) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2021.100272 · Cited by 15
Longhitano, E., Muscolino, P., Re, C. L., Ferrara, S. A., Cernaro, V., Gembillo, G., Tessitore, D., Speranza, D., Figura, F., Santarpía, M., et al. (2023) · Cancers · doi:10.3390/cancers15061891 · Cited by 17
Ari, S. L., Serzan, M. T., Wu, T., Ip, A., Pascual, L., Sinclaire, B., Adams, S., Marafelias, M., Ayyagari, L., Gill, S. K., et al. (2023) · Cancer · doi:10.1002/cncr.34742 · Cited by 17
Hall, J. T., Lui, K., Tan, X. M., Shumway, J., Collichio, F. A., Moschos, S. J., Sengupta, S., Chaudhary, R. T., Quinsey, C. S., Jaikumar, S., et al. (2023) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2023.109920 · Cited by 15
Gao, J., Zhang, P., Nie, X., Tang, M., Yuan, Y., He, L., Wang, X., Ma, J., & Li, L. (2024) · iScience · doi:10.1016/j.isci.2024.109946 · Cited by 16
Restricting datasets to classifiable samples augments discovery of immune disease biomarkers
Glehr, G., Riquelme, P., Kronenberg, K., Lohmayer, R., López‐Madrona, V. J., Kapinsky, M., Schlitt, H. J., Geissler, E. K., Spang, R., Haferkamp, S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49094-3 · Cited by 14
Yu, W., Wang, K., He, Y., Shang, Y., Hu, X., Deng, X., Zhao, L., Ma, X., Mu, X., Li, R., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105267 · Cited by 15
Tian, T., Wang, J., Yin, F., Wu, M., He, W., Wang, X., Zha, Z., & Wang, H. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202102080 · Cited by 15
Zhang, Y., Jin, W., Deng, Z., Gao, B., Zhu, Y., Fu, J., Xu, C., Wang, W., Bai, T., Jiao, L., et al. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.03.046 · Cited by 15
Real-World Adherence to Toxicity Management Guidelines for Immune-Related Adverse Events
Teimouri, A., Minard, L. V., Scott, S. N., Daniels, A. M., & Snow, S. L. (2022) · Current Oncology · doi:10.3390/curroncol29050252 · Cited by 14
Nishikawa, T., Inoue, T., Otsuka, T., Kuno, I., Kukita, Y., Nakamura, H., Ikeda, Y., Yasui, T., Shioyama, W., Oka, T., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0275865 · Cited by 14
Common endocrine system adverse events associated with immune checkpoint inhibitors
Li, Y., Zhao, J., Wang, Y., Xu, Y., Li, R., Zhao, Y., Dong, X., Yao, X., & Li, Y. (2023) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2023.11.005 · Cited by 14
Ahmadnia, A., Mohammadi, S., Yamchi, A., Kalani, M. R., Farazmandfar, T., Khosravi, A., & Memarian, A. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46040183 · Cited by 14
Cancer therapy-related interstitial lung disease
Zhou, C., Deng, H., Yang, Y., Wang, F., Lin, X., Liu, M., Xie, X., Luan, T., & Zhong, N. (2024) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003149 · Cited by 15
Macciò, U., WICKI, A. N., Ruschitzka, F. T., Beuschlein, F., Wolleb, S., Varga, Z., & Moch, H. (2024) · Modern Pathology · doi:10.1016/j.modpat.2024.100683 · Cited by 16
Choi, B., & Kim, D. (2021) · Advanced NanoBiomed Research · doi:10.1002/anbr.202100010 · Cited by 15
Dipasquale, A., Persico, P., Lorenzi, E., Rahal, D., Santoro, A., & Simonelli, M. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001870 · Cited by 15
Safety and Efficacy of PD-1/PD-L1 Inhibitors in Cancer Patients With Preexisting Autoantibodies
Tang, H. J., Geng, R., Xu, X., Wang, Y., Zhou, J., Zhang, S., Zhao, L., Guan, M., & Bai, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.893179 · Cited by 14
Habib, R., Miller, W. H., Papadopoulos, T., Rincon, S. V. D., Berger, C., Molina, M. F., Hudson, M., & Esfahani, K. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-013214 · Cited by 13
Self-citationLi, Y.-L., Jia, X., Du, Y., Mao, Z., Zhang, Y., Shen, Y. L., Sun, H., Liu, M., Niu, G., Wang, J., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.827199 · Cited by 13
Late-Onset Immune-Related Adverse Events in Patients with Advanced Melanoma: The LATENT Study
Pozas, J., Cheruvu, S., Jaganathan, P. P., Ganesan, P., Modi, A., Larkin, J., Cossar, L. H., Olsson-Brown, A. C., Johnson, A., Garbutt, N., et al. (2025) · Cancers · doi:10.3390/cancers17152461 · Cited by 12
Dias, Y., Silva, V. A. O., de Carvalho, M. F., Herchenhorn, R., & Herchenhorn, D. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1712632 · Cited by 13
Chen, P., Li, Z., & Cai, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1188523 · Cited by 12
Genta, S., Lajkosz, K., Yee, N., Spiliopoulou, P., Heirali, A., Hansen, A. R., Siu, L. L., Saibil, S. D., Stayner, L.-A., Yanekina, M., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02851-6 · Cited by 12
Sollena, P., Cappilli, S., Federico, F., Schinzari, G., Tortora, G., & Peris, K. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1889449 · Cited by 12
Esfahani, K., Berg, M. H., Zargham, H., Billick, R. C., Pehr, K., Redpath, M., Roshdy, O., & Miller, W. H. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001831 · Cited by 12
Self-citationWon, T., Kalinoski, H. M., Wood, M. K., Hughes, D. M., Jaime, C. M., Talor, M. V., Lasrado, N., Reddy, J., & Čiháková, D. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4065075 · Cited by 12
He, X., Yu, J., & Shi, H. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.797852 · Cited by 11
Glycoengineering in antigen-specific immunotherapies
Li, Y., Chen, H., Gao, J., Wu, P., & Hong, S. (2024) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2024.102503 · Cited by 10
Engineering antiviral immune-like systems for autonomous virus detection and inhibition in mice
Wang, Y., Xu, Y. C., Tan, C. W., Qiao, L., Chia, W. N., Zhang, H., Huang, Q., Deng, Z., Wang, Z., Wang, X., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-35425-9 · Cited by 11
Euvrard, R., Robert, M., Mainbourg, S., Dalle, S., & Lega, J. (2023) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12966 · Cited by 10
Evangelista, G. F. D. B., Figueiredo, A. B., Silva, M. J. D. B. E., & Gollob, K. J. (2022) · Immunotherapy Advances · doi:10.1093/immadv/ltac008 · Cited by 10
Challenging Dermatologic Considerations Associated with Immune Checkpoint Inhibitors
Park, B. J., Jung, S., Chen, S. T., Dewan, A. K., & Johnson, D. B. (2022) · American Journal of Clinical Dermatology · doi:10.1007/s40257-022-00706-y · Cited by 11
Holdase/Foldase Mimetic Nanochaperone Improves Antibody‐Based Cancer Immunotherapy
Zhang, Y., Fu, H., Chen, J., Xu, L., An, Y., Ma, R., Zhu, C., Liu, Y., Ma, F., & Shi, L. (2022) · Small Methods · doi:10.1002/smtd.202201051 · Cited by 10
Tang, Z., Shi, J., Xu, S., Liu, S., Yin, W., Xiang, Y., Li, J., He, Z., Yao, X., Zhou, L., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-011959 · Cited by 10
Immune Checkpoint Inhibitor-Induced Hepatic Injury: A Clinicopathologic Review
Taherian, M., Chatterjee, D., & Wang, H. (2022) · Journal of Clinical and Translational Pathology · doi:10.14218/jctp.2022.00017 · Cited by 9
Innovative optical imaging strategies for monitoring immunotherapy in the tumor microenvironments
Um‐e‐Kalsoom, Wang, S., Qu, J., & Liu, L. (2024) · Cancer Medicine · doi:10.1002/cam4.70155 · Cited by 8
Ali, S., Arshad, M., Summer, M., Zulfiqar, M., Noor, S., Nazakat, L., & Javed, M. A. (2025) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552251324896 · Cited by 10
Zheng, L., Yang, X., Wei, Y., You, J., Li, H., Liao, J., & Cheng, Y. (2022) · Materials & Design · doi:10.1016/j.matdes.2022.110738 · Cited by 9
Gong, Y., Liu, Y., Jiang, F., & Wang, X. (2024) · Seminars in Ophthalmology · doi:10.1080/08820538.2024.2433636 · Cited by 8
Ugwu, O. P.-C., Nkemjika, A. C., Nnaemeka, U. M., & Onohuean, H. (2025) · Plant Signaling & Behavior · doi:10.1080/15592324.2025.2486076 · Cited by 18
Expert consensus on cancer treatment-related lung injury
Lin, X., Guo, H., Zhao, W., Li, M., Lin, G., Chu, Q., Chen, E., Chen, L., Chen, R., Chu, T., et al. (2025) · Journal of Thoracic Disease · doi:10.21037/jtd-2025-292 · Cited by 8
Fatima, S. N., Arif, F., Khalid, R., Khan, M., & Naseem, K. (2025) · Microbial Pathogenesis · doi:10.1016/j.micpath.2025.107882 · Cited by 11
CAR NK cell therapy for solid tumors: potential and challenges
Yu, Y., & Ho, M. (2025) · Antibody Therapeutics · doi:10.1093/abt/tbaf019 · Cited by 11
Hasan, S., Awasthi, P., Malik, S., & Dwivedi, M. (2022) · Biotechnology and Genetic Engineering Reviews · doi:10.1080/02648725.2022.2147661 · Cited by 8
The role of tumor types in immune-related adverse events
Xu, Q., Hu, J., Wang, Y., & Wang, Z. (2024) · Clinical & Translational Oncology · doi:10.1007/s12094-024-03798-6 · Cited by 9
Lerner, A., Lee, A. J. X., Yan, H., van Griethuysen, J., Bartlett, A. D., Veli, M., Jiang, Y., Luong, M., Naban, N., Kane, C., et al. (2024) · Clinical Oncology · doi:10.1016/j.clon.2024.01.009 · Cited by 8
Wang, X., Yuan, M., Ding, Z., Li, Q., Zhao, Z., Tang, Y., Jiang, T., Adeli, M., Wang, X., Gu, P., et al. (2025) · ACS Nano · doi:10.1021/acsnano.5c04490 · Cited by 7
Treatment of steroid‐resistant checkpoint inhibitor pneumonitis with pirfenidone: A case report
Miao, K., Xu, Y., Xu, W., Zhang, Y., Xu, Y., Tian, X., & Zhang, L. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.13921 · Cited by 7
Hajem, S., Éderhy, S., Champiat, S., Troalen, F., Nolin-Lapalme, A., Berhoune, M., Cauquil, C. A., Martín-Romano, P., Baldini, C., Laparra, A., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.08.045 · Cited by 7
Yin, N., Liu, X., Ye, X., Song, W., Lu, J., & Chen, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.961266 · Cited by 7
Rheumatic adverse events of immune checkpoint inhibitors in cancer immunotherapy
Abdel‐Wahab, N., & Suarez-Almazor, M. E. (2024) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2024.2323966 · Cited by 9
Personalized treatment of immune-related adverse events — balance is required
Martins, F., & Obéid, M. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0400-4 · Cited by 7
Desîlets, A., Elkrief, A., & Routy, B. (2020) · European Urology · doi:10.1016/j.eururo.2020.09.001 · Cited by 7
Self-citation
Metadata
- Authors
- Esfahani, K., Elkrief, A., Calabrese, C., Lapointe, R., Hudson, M., Routy, B., Miller, W. H., & Calabrese, L.
- Affiliations
- McGill University (CA)
- Cleveland Clinic (US)
- Centre Hospitalier de l’Université de Montréal (CA)
- Corresponding author
- Esfahani, Khashayar
- ORCID
- Venue
- Nature Reviews Clinical Oncology
- Published
- 2020-04-03
- Volume
- 17
- Issue
- 8
- Pages
- 504-515
- ISSN
- 1759-4774 (ISSN-L)
- 1759-4782
- OpenAlex
- W3015154527
- Cited by
- 351
- References
- 187
- Citations by year
- 2026: 39 · 2025: 60 · 2024: 65 · 2023: 56 · 2022: 59 · 2021: 51 · 2020: 20
- FWCI
- 4.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Nature Reviews Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- immune-related adverse events, immune checkpoint inhibitors, personalized treatment, immunohistopathology, immune reconstitution, tumor surveillance, autoimmune disease management, immunopathology
- MeSH terms
- Antineoplastic Agents, Immunological, Humans, Immunologic Factors, Immunologic Surveillance, Immunotherapy, Neoplasms, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
